{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:32:29Z","timestamp":1794562349239,"version":"4.9.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early detection of melanoma recurrence and progression remains a clinical challenge, which relies on physical examination and imaging. Circulating tumor DNA offers a noninvasive, dynamic biomarker that may identify molecular recurrence before clinical progression. We aimed to evaluate the prognostic and predictive value of longitudinal, tumor-informed ctDNA testing across multiple melanoma care settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 56 consecutive melanoma patients who underwent serial ctDNA testing using a tumor-informed assay (Signatera\u2122) at a single institution. Fifty-six patients with evaluable ctDNA results were stratified into three cohorts based on the treatment context at the time of ctDNA testing: (A) no active treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), (B) adjuvant therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914), and (C) active treatment for known disease (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922). We evaluated disease-free survival (DFS), overall survival (OS), and longitudinal ctDNA dynamics in relation to clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median clinical follow-up was 48.0 (IQR 24.7\u201394.1) months. In Cohorts A and B (HR 12.3, 95% CI 1.1\u20131138.6), detectable ctDNA at any timepoint was significantly associated with inferior DFS. Conversely, 90% of patients in Cohorts A and B combined with undetectable ctDNA remained recurrence-free. In Cohort C, rising or persistently positive ctDNA was seen in 81.8% of patients who progressed. Longitudinal ctDNA trends were more informative than isolated timepoints, with increases preceding radiologic progression by a median of 11.4 (IQR 5.0\u201313.1) months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Tumor-informed ctDNA testing offers clinically meaningful insight across melanoma care settings. Rising or positive ctDNA frequently anticipates disease progression, supporting its use for MRD surveillance and treatment response monitoring in dermatology and oncology practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15931-5","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:03:00Z","timestamp":1775124180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal tumor-informed ctDNA monitoring for recurrence and treatment response in melanoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Olivia","family":"Sleeper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Fortino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Woo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil I.","family":"Daud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay V.","family":"Maker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"15931_CR1","first-page":"760","volume":"387","author":"J Tie","year":"2022","unstructured":"Tie J, Lo SN, Gibbs P. Circulating tumor DNA guiding adjuvant therapy in colon cancer. reply. N Engl J Med. 2022;387:760.","journal-title":"N Engl J Med"},{"key":"15931_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","volume":"29","author":"RJ Lee","year":"2018","unstructured":"Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, et al. Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma. Ann Oncol. 2018;29:490\u20136.","journal-title":"Ann Oncol"},{"key":"15931_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/cncr.35263","volume":"130","author":"AC Tan","year":"2024","unstructured":"Tan AC, Lai GGY, Saw SPL, Chua KLM, Takano A, Ong B-H, et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer. 2024;130:1758\u201365.","journal-title":"Cancer"},{"key":"15931_CR4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","volume":"129","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Krinshpun S, Kalashnikova E, Sudhaman S, Ozturk Topcu T, Nichols M, et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129:1723\u201334.","journal-title":"Cancer"},{"key":"15931_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","volume":"26","author":"MM Syeda","year":"2025","unstructured":"Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 2025;26:641\u201353.","journal-title":"Lancet Oncol"},{"key":"15931_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","volume":"158","author":"L Gracie","year":"2021","unstructured":"Gracie L, Pan Y, Atenafu EG, Ward DG, Teng M, Pallan L, et al. Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. Eur J Cancer. 2021;158:191\u2013207.","journal-title":"Eur J Cancer"},{"key":"15931_CR7","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","volume":"22","author":"S Marchisio","year":"2024","unstructured":"Marchisio S, Ricci AA, Roccuzzo G, Bongiovanni E, Ortolan E, Bertero L, et al. Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment. J Transl Med. 2024;22:1074.","journal-title":"J Transl Med"},{"key":"15931_CR8","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1038\/s41598-020-61818-1","volume":"10","author":"J Knuever","year":"2020","unstructured":"Knuever J, Weiss J, Persa O-D, Kreuzer K, Mauch C, Hallek M, et al. The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci Rep. 2020;10:4940.","journal-title":"Sci Rep"},{"key":"15931_CR9","doi-asserted-by":"publisher","unstructured":"V\u00e1raljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A et al. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. JCO Precis Oncol. 2019;3:PO.18.00229. https:\/\/doi.org\/10.1200\/PO.18.00229.","DOI":"10.1200\/PO.18.00229"},{"key":"15931_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","volume":"30","author":"L Tan","year":"2019","unstructured":"Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, et al. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Ann Oncol. 2019;30:804\u201314.","journal-title":"Ann Oncol"},{"key":"15931_CR11","doi-asserted-by":"crossref","unstructured":"Rodrigues M, Ramtohul T, Rampanou A, Sandoval JL, Houy A, Servois V, et al. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp. Nat Commun. 2024;15:8851.","DOI":"10.1038\/s41467-024-53145-0"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15931-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15931-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:24:01Z","timestamp":1781645041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15931-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15931"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15931-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Helsinki Declaration and were approved by the University of California, San Francisco Institutional Review Board with a waiver of informed consent (22-37690).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Tsai reported receiving institutional research funding from AstraZeneca, ABM Therapeutics, BioAtla, Oncosec, Pfizer, Replimune, Regeneron, Genentech, and OnKure; and serving on the advisory board for and receiving institutional research funding from BMS outside the submitted work. Dr. Chan reported receiving institutional research funding from Nanobiotix. No other disclosures were reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"634"}}